In Vitro Diagnostics
Our cell-free DNA extraction In Vitro Diagnostic (IVD) microdevice
Liquid Biopsy is a rapidly evolving non-invasive alternative to surgical biopsies, which enables the discovery of a wide range of information about a tumor through a simple blood sample. Traces of the cancerous DNA in the blood can be used for the diagnosis of cancer, predicting cancer recurrence and to give clues about which treatments are most likely to work for individual patients.
The Global Liquid Biopsy Market was valued at USD 1.244 billion in 2018 and is projected to reach USD 12.062 billion by 2025, growing at a CAGR of 38.3% from 2017 to 2025
Non-Invasive Prenatal Testing (NIPT) is a rapidly evolving non-invasive prenatal diagnostic modality. Traces of fetal DNA in the maternal blood can be used for the early diagnosis of fetal inborn genetic diseases. The global non-invasive prenatal testing market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5%.
Efficient cell-free DNA isolation is a critical step in determining whole liquid biopsy and NIPT sensitivity. Current extraction methods yield modest quantities of cfDNA with significant fragmentation, which adversely effects the diagnostic accuracy of all current liquid biopsy and NIPT methodologies.
Santersus is developing a proprietary cell-free DNA extraction In Vitro Diagnostic (IVD) micro-device based on NucleoCapture technology leveraging the ability of histone H1.3 to bind tumor secreted cell-free DNA with single digit nanomolar DNA binding constants.
We believe Santersus cell-free DNA extraction IVD micro-device will significantly improve the sensitivity and diagnostic utility of existing liquid biopsy and NIPT assays. This will open up new diagnostic opportunities in cancer and non-invasive prenatal screening.